Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Alzheimer's Dementia | Illinois
PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Apr 16, 2023--